![Natarajan Sethuraman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 1 Mio $ am 31.07.2026
Natarajan Sethuraman currently works at Entrada Therapeutics, Inc., as President-Research & Development from 2024.
Dr. Sethuraman also formerly worked at Merck & Co., Inc., as Executive Director & Head-GlycoFi Site from 2012 to 2016 and Medical Enzymes AG, as Senior Scientist.
Dr. Sethuraman received his graduate degree and doctorate degree from Indian Agricultural Research Institute and undergraduate degree from Tamilnadu Agricultural University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.09.2026 | 214’238 ( 0.55% ) | 1 Mio $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ENTRADA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2017 |
| Unternehmen | Position | Ende |
|---|---|---|
| MERCK & CO., INC. | Direktor/Vorstandsmitglied | 01.07.2016 |
Medical Enzymes AG
 Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Indian Agricultural Research Institute
 Indian Agricultural Research Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tamilnadu Agricultural University
 Tamilnadu Agricultural University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Health Services |
Entrada Therapeutics, Inc.
 Entrada Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for rare neuromuscular diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
